• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

Dr. George Gorodeski Assumes Role As CytoCore's Lead Research Scientist

Posted on: Tuesday, 25 April 2006, 12:01 CDT

CytoCore, Inc. (OTCBB:MCDG) announces Dr. George Gorodeski is assuming the position as lead research scientist as well as head of the Company's Medical Advisory Board.

George Gorodeski, MD, MSc and PhD, is Gynecologist and Reproductive Endocrinologist in the Department of Obstetrics and Gynecology at University Hospitals of Cleveland, and Professor of Reproductive Biology at CASE (Case Western Reserve) University. He also holds professorships at CASE departments of Oncology, and Physiology and Biophysics. Dr. Gorodeski has been lead or co-investigator on over 40 basic science projects and FDA-approved clinical trials. He has written over 170 publications, including 95 peer-reviewed articles in his areas of research, as well as 5 patents filed. Dr. Gorodeski was the original developer and patented the Company's e2 Collector; the originator of combining multiple biomarkers into the "cocktail" approach for cervical cancer screening; and developer of the concept of mapping of cervical lesions. Dr. Gorodeski's academic career combines a busy clinical practice, active basic and clinical research, and professional service. Among his service responsibilities he serves as President for the North American Menopause Society (2005-2006); Chairperson of an NIH Study Section, and Chairman of the OB-GYN departmental Investigational Review Board.

CytoCore's CEO, Dr. David Weissberg said, "Dr. Gorodeski has agreed to direct our basic and clinical research. Dr. Gorodeski has consistently brought forward new and exciting advancements in the detection and treatment of Cervical and Endometrial cancers, as exemplified by the two new products he recently developed and with UHC licensed to CytoCore: the P2X7 Bio-Marker and the Drug Delivery System. By all accounts Dr. Gorodeski operates a highly efficient and very productive University lab. He will use his knowledge and expertise to guide the research toward optimizing the trials and development work to bring these products to commercial readiness. Dr. Gorodeski will guide and conduct the clinical research in his lab at the Department of Obstetrics and Gynecology at UHC. We are fortunate that he has chosen CytoCore as his partner to develop and commercialize the products of his creativity. We look with great enthusiasm and expectations to successfully undertake trials on the P2X7 Bio-Marker for a uterine cancer screen that UHC has recently licensed to us, and to integrating this product into the CytoCore InPath System. With this screen and the drug delivery system successfully tested and ready for market, the InPath System will become the unquestioned leader in the area of Cervical and Endometrial cancer detection and prevention. Dr. Gorodeski, to me, represents all that is right in the world of medicine, medical research and service. It is a real pleasure working with this individual."

Dr. Gorodeski stated, "I am delighted for the opportunity to collaborate and partner with CytoCore. The Company combines a strong portfolio of novel biotechnology, some of which I had the privilege to help develop, with a focused vision on product development through trial processes and into full product commercialization. To be able to carry projects from the early stage of invention through development to clinical application is what most clinical scientists strive for. It is this single minded focus along with the commitment, energy, and dedication that the new management has demonstrated that makes my participation with the company very attractive to me. The new products, the P2X7 Bio-Marker and the Drug Delivery System, will substantially strengthen and enhance the InPath System's capabilities, and when materialized into commercial products they will improve patient care and save lives. I look forward to working closely with CytoCore and to bring these products through their trials to commercial readiness rapidly."

About CytoCore Inc.

CytoCore develops cost-effective cancer screening systems, which can be utilized in a laboratory or at the point-of-care, to assist in the early detection of cervical, gastrointestinal, and other cancers. The InPath(TM) System is being developed to provide medical practitioners with a highly accurate, low-cost, cervical cancer screening system that can be integrated into existing medical models or at the point-of-care.

More information is available at: www.Molecular-Dx.com

About University Hospitals Health System

University Hospitals Health System is the region's premier healthcare delivery system, serving patients at more than 150 locations throughout northern Ohio.

Committed to advanced care and advanced caring, University Hospitals Health System offers the region's largest network of primary care physicians, outpatient centers and hospitals. The System also includes a network of specialty care physicians, skilled nursing, elder health, behavioral health, rehabilitation and home care services, managed care and insurance programs and occupational health and wellness.

The Health System's tertiary medical center, University Hospitals of Cleveland, is an affiliate of Case Western Reserve University. Together, they form the largest center for biomedical research in the State of Ohio. Included are Rainbow Babies & Children's Hospital, among the nation's best children's hospitals; Ireland Cancer Center, a National Cancer Institute-designated Comprehensive Cancer Center (the nation's highest designation); and MacDonald Women's Hospital, Ohio's only hospital for women.

Nearly 25,000 physicians and employees comprise University Hospitals Health System and its partner hospitals, ranking it northern Ohio's second largest employer. University Hospitals Health System's goal is to provide comprehensive primary and community-based care-the kind of healthcare people need most-as well as access to the highest quality specialty care when necessary.

Certain statements in this release are forward-looking. These statements are based on CytoCore's current expectations and involve many risks and uncertainties, such as the company's inability to obtain sufficient financing, the possibility that clinical trials will not substantiate CytoCore's expectations with respect to the InPath(TM) System, and other factors set forth in reports and documents filed by CytoCore with the Securities and Exchange Commission. Actual results may differ materially from CytoCore's current expectation depending upon a number of factors affecting the Company's business. These factors include, among others, risks and uncertainties detailed in the Company's periodic public filings with the Securities and Exchange Commission, including but not limited to the Company's Annual Report on Form 10-K for the year ended December 31, 2004 and its Quarterly Reports on Form 10-QSB for the quarters ended June 30, 2005 and September 30, 2005. Except as expressly required by law, CytoCore undertakes no obligation to publicly update or revise any forward-looking statements contained herein.

Source: Business Wire

More News in this Category